tiprankstipranks
Advertisement
Advertisement

Haleon Cancels 8.9 Million Shares in Ongoing Buyback Programme

Story Highlights
  • Haleon repurchased and cancelled about 8.9 million shares under its March 2026 buyback programme.
  • The buyback reduces voting-share count to 8.92 billion, slightly boosting EPS and altering disclosure thresholds.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Haleon Cancels 8.9 Million Shares in Ongoing Buyback Programme

Claim 30% Off TipRanks

Haleon PLC ( (GB:HLN) ) has issued an update.

Haleon plc has executed a series of share repurchases, buying 8,939,706 ordinary shares for cancellation under the share buyback programme it launched earlier in March 2026. The transactions were carried out across multiple venues, including the London Stock Exchange and Cboe UK platforms, over five trading days from 23 to 27 March.

Following settlement of these purchases, Haleon’s registered share capital stands at 8,932,831,335 ordinary shares, of which 12,548,735 are held in treasury, leaving 8,920,282,600 shares with voting rights. The reduction in free-float equity marginally enhances earnings per share and may signal continued management confidence in the business, while also affecting investors’ calculations for regulatory disclosure thresholds under U.K. transparency rules.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc is a global consumer health company focused on improving everyday health through over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory, digestive and therapeutic skin health, with well-known brands such as Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren, used by over one billion consumers worldwide.

Average Trading Volume: 19,549,535

Technical Sentiment Signal: Hold

Current Market Cap: £32.76B

For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1